11 February 2021 - The Biosafety Advisory Council issues a positive advice (with conditions) for this deliberate release
File:
Trial reference:
Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, with pembrolizumab, in Patients with Unresectable Stage III / IV Cutaneous Melanoma and with Stage IV NSCLC